Hepatitis C virus cure with direct-acting antivirals: Clinical, economic, societal and patient value for China

Xie, Qing; Xuan, Jianwei; Tang, Hong; Ye, Xiao-Guang; Xu, Peng; Lee, I-Heng; Hu, Shanlian

doi:10.4254/wjh.v11.i5.421

Cited by 15 publications

(8 citation statements)

References 119 publications

(126 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…16,17 Our study endorsed the results presented by Morad et al and Xie Q et al in Egyptian and Chinese populations respectively. 18,19 Similarly, Kesen O et al have the similar results in Turkish populations. 20 Contrary to our results, Thuluvath PJ et al showed only marginal improved in QoL after eradication of HCV.…”

Section: Discussionmentioning

confidence: 54%

Successful Eradication of Hepatitis-C Virus with Sofosbuvir based Antiviral treatment results in improvement in quality of life in cirrhotic patients

Ali¹,

Raja

Choudhry³

et al. 2022

Pak J Med Sci

View full text Add to dashboard Cite

Objectives: To document improvement in quality of life in patients with Hepatitis-C related cirrhosis after successful eradication of the virus. Methods: In this observational cohort study conducted at Fatima Memorial Hospital from September 2015 to July 2017, patients with HCV were assessed for improvement in quality of life by using FACIT-F questionnaire. We compared the Quality of life (QOL) score before the start of treatment with DAAs and after achieving SVR12 in various aspects of quality of life including physical, emotional, functional and social well-being. Results: A total of 71 patients, 52 (73%) were CTP class A, 18 (25%) in B and one (1.4%) in C. The mean score of QOL before AVT was 23.93±7.04 and after achieving SVR it was 36.83±6.36 (P-value <0.001). In the subcategories, score of functional wellbeing, physical well-being and social wellbeing had significantly improved except emotional wellbeing scores. All scores improved across the spectrum of patients in the CTP class A and B. There was only one patient in the CTP-C class. Conclusion: Chronic HCV infection complicated by cirrhosis causes a significant decline in quality of life. There was a marked improvement in the functional, social and physical health of the patients after eradication of Hepatitis-C with anti-viral therapy except emotional health of the individuals. doi: https://doi.org/10.12669/pjms.38.4.4537 How to cite this:Ali B, Raja IH, Choudhry A, Nawaz AA. Successful Eradication of Hepatitis-C Virus with Sofosbuvir based Antiviral treatment results in improvement in quality of life in cirrhotic patients. Pak J Med Sci. 2022;38(4):---------. doi: https://doi.org/10.12669/pjms.38.4.4537 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

Section: Discussionmentioning

confidence: 54%

Successful Eradication of Hepatitis-C Virus with Sofosbuvir based Antiviral treatment results in improvement in quality of life in cirrhotic patients

Ali¹,

Raja

Choudhry³

et al. 2022

Pak J Med Sci

View full text Add to dashboard Cite

show abstract

“…[ 15 ] According to Xie et al ., a universal DAA adoption would reduce the cases of incident decompensated cirrhosis, hepatocellular carcinoma, liver transplants, and liver-related deaths by 61%, 45%, 50%, and 61%, respectively. [ 16 ]…”

Section: Discussionmentioning

confidence: 99%

Impact of Drug Use Policy on the Appropriate Use of Direct Acting Antiviral Agents for Hepatitis C in Saudi Arabia

Alotaibi

Shamas

Ansari

et al. 2021

Journal of Pharmacy and Bioallied Sciences

View full text Add to dashboard Cite

Background: Ministry of National Guard–Health Affairs in Saudi Arabia developed a new policy for the use of direct antiviral agents (DAAs) for hepatitis C. The present study was conducted to evaluate prescribers' compliance and the impact of the policy on DAAs appropriate use. Materials and Methods: This study was conducted at King Abdul Aziz Medical City in Jeddah, Saudi Arabia. The study compares patients' data during 1 year before and 1 year after policy initiation. The primary outcomes were compliance to monitoring parameters, appropriateness of treatment and treatment eligibility. Secondary outcomes included sustained virologic response at 12 weeks, documentation of potential drug–drug interactions and treatment costs. Independent samples t -test and Chi-square test were used when applicable. A P < 0.05 was considered statistically significant. Results: One hundred and three patients were included in analysis (46 before and 57 after policy). Prescriber compliance to baseline monitoring parameters was 67.4% before policy and 82.5% after-policy ( P = 0.076). International normalized ratio (INR) was requested in 84.8% of cases before policy compared to 96.5% after-policy ( P = 0.036). Treatment options offered to patients were appropriate in 52.2% of cases before policy and in 82.5% after-policy ( P = 0.001). Conclusion: There is a significant improvement in the baseline monitoring of INR. Treatment options offered after policy implementation were significantly more appropriate.

show abstract

“…Patients with hepatitis B cirrhosis have benefited from years of oral antiviral therapy 13. On the other hand, for hepatitis C patients, direct acting antivirals as a new effective medication were not available during the study period 14…”

Section: Discussionmentioning

confidence: 99%

<p>Biomarkers and sociodemographic factors predicting one-year readmission among liver cirrhosis patients</p>

Dai

Zhao

et al. 2019

TCRM

View full text Add to dashboard Cite

Background Hospital readmissions of patients with cirrhosis is a current problem in China. This study aims to estimate the readmission rate at one year after discharge and to identify associated risk factors of hospital readmission. Methods Between January 2012 and December 2015, 3,402 patients admitted with cirrhosis were included in the study. The primary outcome was one-year inpatient readmission. Principal components analysis was conducted on the laboratory test indicators to reduce the number of dimensions. Univariate and multivariate analyses were performed using clinical and demographic data to identify independent associated factors of readmission within one year. The odds ratio (OR) and 95% confidence interval were used to assess the strength of association for each factor. Results Two dimensions, namely “liver function” and “renal function”, were revealed. Patients with a longer length of stay in the index admission (OR: 1.03; 95% CI: 1.03–1.04) and a higher dimension score of liver function (OR: 1.09; 95% CI: 1.05–1.13) were more likely to be readmitted within one-year. Older patients had a significantly higher odds of one-year readmission than younger patients (OR: 1.61; 95% CI: 1.22–2.11), patients who were married had a higher odds than those who were single (OR: 1.62; 95% CI: 1.12–2.36), and patients with hepatitis C virus were more likely to be readmitted within one year than patients with hepatitis B virus (OR: 1.51; 95% CI: 1.19–1.91). Conclusion Biomarkers and sociodemographic factors can identify patients at high risk for readmission within one year. Our data indicates the need to emphasize proper liver care to older patients who have been hospitalized for a long time.

show abstract

Hepatitis C virus cure with direct-acting antivirals: Clinical, economic, societal and patient value for China

Cited by 15 publications

References 119 publications

Successful Eradication of Hepatitis-C Virus with Sofosbuvir based Antiviral treatment results in improvement in quality of life in cirrhotic patients

Successful Eradication of Hepatitis-C Virus with Sofosbuvir based Antiviral treatment results in improvement in quality of life in cirrhotic patients

Impact of Drug Use Policy on the Appropriate Use of Direct Acting Antiviral Agents for Hepatitis C in Saudi Arabia

<p>Biomarkers and sociodemographic factors predicting one-year readmission among liver cirrhosis patients</p>

Contact Info

Product

Resources

About